4.7 Review

Nanotechnology and Nanomedicine: A Promising Avenue for Lung Cancer Diagnosis and Therapy

期刊

ENGINEERING
卷 7, 期 11, 页码 1577-1585

出版社

ELSEVIER
DOI: 10.1016/j.eng.2020.04.017

关键词

Nanomedicine; Lung cancer; Diagnosis; Therapy

资金

  1. National Program on Key Basic Research Project [2020YFA0211100]
  2. National Natural Science Foundation of China [51872205, 51922077, 81602412]
  3. Fundamental Research Funds for the Central Universities, Training Plan of Outstanding Young Medical Talents, Shanghai Municipal Commission of Health and Family Planning [2017YQ050]
  4. Scientific Research Project of Shanghai Municipal Commission of Health and Family Planning [2016Y0121]
  5. Natural Scientific Foundation of Shanghai [134119b1002]
  6. Outstanding Young Scientific Researcher of Shanghai Pulmonary Hospital

向作者/读者索取更多资源

Lung cancer, a leading cause of cancer-related deaths globally, has prompted the development of nanotechnology and nanomedicine approaches to improve early diagnosis and individualized treatment options. While successful in research, challenges remain in the clinical translation of nanomedicine due to limited understanding of interactions with biology and manufacturing challenges.
Lung cancer is a leading cause of cancer-related death worldwide, with a very poor overall five-year survival rate. The intrinsic limitations associated with the conventional diagnosis and therapeutic strategies used for lung cancer have motivated the development of nanotechnology and nanomedicine approaches, in order to improve early diagnosis rate and develop more effective and safer therapeutic options for lung cancer. Cancer nanomedicines aim to individualize drug delivery, diagnosis, and therapy by tailoring them to each patient's unique physiology and pathological features-on both the genomic and proteomic levels-and have attracted widespread attention in this field. Despite the successful application of nanomedicine techniques in lung cancer research, the clinical translation of nanomedicine approaches remains challenging due to the limited understanding of the interactions that occur between nanotechnology and biology, and the challenges posed by the toxicology, pharmacology, immunology, and large-scale manufacturing of nanoparticles. In this review, we highlight the progress and opportunities associated with nanomedicine use for lung cancer treatment and discuss the prospects of this field, together with the challenges associated with clinical translation. (C) 2021 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据